Table 2.
Meta-analysis of the parameters of accuracy in different commercial molecular in vitro diagnostic tests for the detection of SARS-CoV-2 stratified by brand name
| Brand name | Sample | No. of studies | Pooled sensitivity (95% CI) | Pooled specificity (95% CI) |
|---|---|---|---|---|
| Xpert Xpress SARS-CoV-2 test (Cepheid) | Nasopharyngeal and nasal swab | 2 | 0.956 (0.849–0.988) I2 = 63.75% |
0.964 (0.779–0.995) I2 = 54.54% |
| Simplexa COVID-19 Direct (DiaSorin Molecular LLC) | Nasopharyngeal, oropharyngeal, and nasal swab | 6 | 0.920 (0.862–0.955) I2 = 42.13% |
0.970 (0.937–0.986) I2 = 18.32% |
| Cobas SARS-CoV-2 (Roche Molecular Systems, Inc.) | Nasopharyngeal, throat, sputum, saliva, stool, aspiration, and serum | 2 | 0.963 (0.836–0.993) I2 = 0% |
0.998 (0.991–1.000) I2 = 0% |
| ID NOW COVID-19 (Abbott Diagnostics Scarborough, Inc.) | Nasopharyngeal and nasal swab | 4 | 0.916 (0.805–0.966) I2 = 65.42% |
0.942 (0.708–0.991) I2 = 79.63% |
| Allplex 2019-nCoV Assay (Seegene Inc.) | Nasopharyngeal, oropharyngeal, and nasal swab | 2 | 0.978 (0.916–0.995) I2 = 0% |
0.982 (0.884–0.998) I2 = 0% |
| Panther Fusion SARS-CoV-2 (Hologic, Inc.) | Nasopharyngeal swabs, deep throat saliva, and lower respiratory tract | 2 | 0.994 (0.956–0.999) I2 = 0% |
0.982 (0.931–0.995) I2 = 0% |
| BioFire COVID-19 Test (BioFire Defense, LLC) | Nasopharyngeal, oropharyngeal, and nasal swab | 2 | 0.967 (0.743–0.997) I2 = 64.77% |
0.982 (0.931–0.995) I2 = 0% |